Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Arance

Showing results (51-60 of 92) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006Omid Hamid, Caroline Robert, Adil Daud, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
The Lancet. Oncology|June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialMichael A Davies, Philippe Saiag, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateEvan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
The Lancet. Oncology|March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
The Lancet. Oncology|September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant MelanomaJean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic MelanomaReinhard Dummer, Shibing Deng, Tao Xie, et al.
Journal for Immunotherapy of Cancer|January 31, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case seriesCatriona Harvey, Kazi J Nahar, Janet McKeown, et al.
Pageof 10

Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006Omid Hamid, Caroline Robert, Adil Daud, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
The Lancet. Oncology|June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialMichael A Davies, Philippe Saiag, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateEvan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
The Lancet. Oncology|March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
The Lancet. Oncology|September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant MelanomaJean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic MelanomaReinhard Dummer, Shibing Deng, Tao Xie, et al.
Journal for Immunotherapy of Cancer|January 31, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case seriesCatriona Harvey, Kazi J Nahar, Janet McKeown, et al.
Pageof 10